Abbott, The Abbott Fund Provide $2 Million in Additional Relief to Help Families Affected By Hurricane Maria, Earthquake in Mexico

Total support for relief efforts following earthquakes in Mexico and Hurricanes Harvey, Irma and Maria is $4.25 million in products and funding.

People walk on the street next to debris after the area was hit by Hurricane Maria in Guayama, Puerto Rico Sept. 20, 2017. / REUTERS

Abbott (No. 10 on the DiversityInc Top 50 Companies list)  and its foundation, the Abbott Fund, are providing $2 million in additional grants and products to support relief efforts and help families recover from Hurricane Maria in the Caribbean, and the earthquake in Central Mexico.  This builds on earlier aid for Hurricanes Harvey and Irma, and the earthquake in Southern Mexico. To date, Abbott and the Abbott Fund have provided $4.25 million in funding and nutrition and healthcare products to help with relief efforts in recent weeks.


"Our thoughts, and our actions, are focused right now on how we can help our colleagues and the many families across Mexico, the Caribbean and in the U.S. who are coping with the recent hurricanes and earthquakes," said Miles D. White, chairman and chief executive officer, Abbott. "We hope our assistance will meet critically urgent needs as well as help support rebuilding these communities in the weeks and months ahead."

Mexico Earthquakes

Abbott and the Abbott Fund are providing $1 million in relief to help communities in Central Mexico affected by the recent earthquake. The Abbott Fund is providing $750,000 in grants to the Mexican Red Cross and Direct Relief, and Abbott is donating $250,000 in nutrition products and medicines, including donations to the National Chamber of the Pharmaceutical Industry (CANIFARMA) to support the government's relief efforts.

This support builds on an earlier $250,000 in funding and product donations for relief efforts following the earthquake in Southern Mexico. The Abbott Fund provided $50,000 to Direct Relief, and Abbott provided $200,000 in nutrition products and medicines to support the government's relief efforts in Chiapas and Oaxaca.

Altogether, Abbott and the Abbott Fund are providing $1.25 million in support for relief efforts following the earthquakes in Mexico.

Hurricane Relief

Abbott and the Abbott Fund are providing $1 million in additional relief to help communities in Puerto Rico and other Caribbean islands affected by Hurricane Maria. This includes $750,000 in grants from the Abbott Fund to the American Red Cross, Americares, Direct Relief, Feeding America and Heart to Heart International, and $250,000 in donated Abbott nutrition and healthcare products to relief organizations.

Abbott and the Abbott Fund previously announced $1 million in grants and products to support Hurricane Irma relief efforts in the Southeastern U.S., Puerto Rico and other affected islands in the Caribbean. This includes $900,000 in grants from the Abbott Fund to the American Red Cross, Direct Relief and Feeding America, and $100,000 in donated Abbott nutrition and healthcare products to relief organizations.

Abbott and the Abbott Fund also previously announced $1 million in donations to support Hurricane Harvey relief efforts in Texas and Louisiana. This includes $900,000 in grants from the Abbott Fund to the American Red Cross, Americares and Direct Relief, and $100,000 in donated Abbott nutrition and healthcare products to relief organizations.

The donations following Hurricanes Irma, Harvey and Maria also build on earlier work with our partners Direct Relief and Feeding America to help communities prepare for the 2017 hurricane season. Abbott nutrition and healthcare products were stored at health clinics and food banks in advance of hurricane season in Florida, Louisiana, Puerto Rico and Texas. As a result, these clinics and food banks were able to quickly respond to meet immediate needs following Hurricanes Harvey and Irma.

Altogether, the combined Abbott and Abbott Fund support for hurricane preparation and relief is $3 million in products and grants to help families in affected areas.

Connect with Abbott at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

The Abbott Fund is a philanthropic foundation established by Abbott in 1951. The Abbott Fund's mission is to create healthier global communities by investing in creative ideas that promote science, expand access to healthcare and strengthen communities worldwide. For more information on the Abbott Fund, visit www.abbottfund.org.

Abbott: Connected Devices Turn Data Into Better Health

Abbott's Robert Ford Joins a Panel Discussing the Potential for Connected Medical Devices to Improve Patient Care and Drive Better Outcomes.

Originally Published by Abbott.

Today's medical devices are creating terabytes of information that gives patients, doctors and health providers real-time insight into someone's vital statistics, heart health and even bloodwork.

But can all this new information really make someone healthier?

Read More Show Less

Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management

State-of-the-art multi-assay test system helps people with diabetes get the HbA1c results they need within three minutes — allowing more time for consultation and care during a single healthcare visit.

Originally Published by Abbott.

Abbott announced the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit.

Read More Show Less

Abbott's Xience Sierra Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan.

Originally Published by Abbott.

Abbott announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases.

XIENCE Sierra was designed to help doctors more easily treat people with difficult-to-treat blockages that involve multiple or totally blocked arteries or complications such as diabetes. Complex cases are increasingly prevalent as people with coronary artery disease are living longer.

"Extensive clinical data and 10 years of real-world experience with the XIENCE family of stents provide doctors with confidence that they are treating their patients with one of the safest stents available," said Chuck Brynelsen, senior vice president of Abbott's vascular business. "National reimbursement of XIENCE Sierra will provide people in Japan with greater access to this life-changing technology that can help them live their best lives."

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan. National reimbursement in Japan will enable doctors to treat more patients with XIENCE Sierra through the country's health insurance plans. XIENCE Sierra was approved in Japan on April 4, 2018, received CE Mark in Europe late last year, and is under review with the U.S. Food and Drug Administration.

XIENCE has been studied in over 100 clinical trials and in 10 years of global real-world experience. Its safety profile is unprecedented with consistent low rates of stent thrombosis, even in complex cases. More than eight million people worldwide have received a XIENCE stent since its initial regulatory approval.